UBS Downgrades Cepheid (CPHD) to Neutral
More News related to CPHD
- Cepheid Receives Health Canada License for First Molecular Diagnostic Test for MRSA and S. aureus Soft Tissue Infections
- Cepheid Launches First On-Demand Molecular Diagnostic Test for Clostridium Difficile Into European Market
- Cepheid to Webcast Upcoming Financial Presentations
- Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized 'Moderate Complexity' by FDA
- Notable Mergers and Acquisitions of the Day 11/03: MON, CPHD
More News related to Downgrades
- Friedman Billings Starts Aircastle (AYR) at Underperform
- Friedman Billings Starts Netflix (NFLX) at Market Perform
- Credit Suisse Starts 3PAR (PAR) at Neutral
- Credit Suisse Starts Netezza (NZ) at Neutral
- FBR Starts Amazon.com (AMZN) at Market Perform
UBS downgrades Cepheid (Nasdaq: CPHD) from Buy to Neutral with a $23 price target.
Shares of Cepheid closed at $20.95 yesterday.
Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for genetic testing in the clinical molecular diagnostic, industrial, and biothreat markets.
Related Categories
DowngradesStocks Mentioned
-1.88Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
